CancerResearch News & Analysis

Intensity Therapeutics (INTS) Resumes Patient Dosing in Swiss Trial

Intensity Therapeutics (INTS) has resumed patient dosing in its Swiss clinical trial, following a temporary suspension. The company aims to explore the effects of its cancer treatment in this study. This resumption could potentially lead to significant advancements in cancer therapy, depending on the trial results. Ordinary investors should monitor this development closely, as it may impact the company's future performance and stock values.